ArriVent BioPharma, Inc. (AVBP) stock

AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$13.01−0.06 (-0.46%)

Close on Nov 13, 2026Market cap $641.49MP/E –Yield –

ArriVent BioPharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -$180.56M.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$180.56M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$44.03M	–
Q2 FY2026	Jun 30, 2026	-$53.21M	–
Q1 FY2026	Mar 31, 2026	-$46.67M	–

See a number that looks wrong?